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Membrane transporters play a critical role in drug response as they provide the targets for many 
commonly used drugs and are major determinants of drug absorption, distribution, and elimination. 
Most of them belong to one of the two major super-families of membrane transport proteins, the ATP-
binding cassette (ABC) transporters, and the solute carrier (SLC) transporters. They are subject to both 
genotypic and phenotypic polymorphisms, and variation in drug transporters may be the reason for 
inter-individual variability in pharmacokinetic disposition, efficacy, and toxicity of drug transporter 
substrates. The growing number of publications reporting genetic population data for the solute carrier 
transporters in particular shows their importance, as well as the increased interest in investigating them 
in most recent pharmaco-genetics/genomics research projects. These publications range from 
reporting baseline frequency distributions of SNPs of genes important in drug transport, discovering 
new genetic variants of these genes, and/or describing genotyping projects to identify probable 
responders or non-responders to therapy, or to predict exposure levels in different patients. This paper 
reviews the solute carrier transporters and highlights the fact that there is much to be learnt from 
characterizing human genomic variation in South Africa and sub-Saharan Africa, especially with 
regards to health applications. Genomic diversity in this region is indeed relatively under-studied 
despite being home to significant portion of human genomic diversity. 
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HUMAN GENETIC VARIATION 
 
Human genetic variation has implications on a broad 
range of biological and medical disciplines. For this 
reason, the study of human genetic diversity is relevant to 
a variety of research areas including human and popula-
tion genetics, molecular biology, evolutionary biology, 
biological anthropology, health sciences and clinical 





Abbreviations: ABC, ATP-binding cassette; SNPs, single 
nucleotide polymorphisms; VNTR, variable number of tandem 
repeat polymorphisms; PGx, pharmacogenomics; PGt, 
pharmacogenetics; MDR, multidrug resistance; SLC, solute 
carrier; OCTs, organic cation transporters; OATs, organic 
anion transporters; OCTNs, organic zwitterion/cation 
transporters; MATE, multidrug and toxin extrusion. 
human genome only recently became apparent after  
almost the complete DNA sequences of the human 
genome became available (Brockmoller and Tzvetkov, 
2008). One can extrapolate that very soon several human 
individuals will be entirely sequenced and that this will 
provide a more clear understanding of inter-individual 
variation in human genomes (Brockmoller and Tzvetkov, 
2008). At the present time about 12 million single nucleo-
tide polymorphisms (SNPs) have been identified in the 
human genome (Brockmoller and Tzvetkov, 2008). In 
addition, there are probably more than 100,000 insertions 
and deletions. There is also a large class of genetic varia-
tions summarized as variable number of tandem repeat 
polymorphisms (VNTR) (Brockmoller and Tzvetkov, 2008). 
These VNTRs include variable numbers of dinucleotide 
repeats, such as a variable number of TA in the TATA 
box in the core promoter of bilirubin glucuronyltransferase  
 




UGT1A1 and larger repeat units, such as the 16 amino 
acid (48 bp) repeat in the dopamine D4 receptor 
(Brockmoller and Tzvetkov, 2008). It was only recently 
that we have learned that there are at least 1500 large 
genomic segments occurring interindividually in variable 
copy numbers (Brockmoller and Tzvetkov, 2008). 
Variation in the human genome has a wide variety of 
medical and health implications. Genomic variation is 
believed to be the most important cause of variable 
response to drugs and other xenobiotics. Susceptibility to 
almost all diseases is also determined to some extent by 
genetic variation (Brockmoller and Tzvetkov, 2008). For 
this reasons, and driven by the advances in molecular 
biology, pharmacogenetics has evolved within the past 
40 years from a niche discipline to a major driving force 
of clinical pharmacology, and it is currently one of the 
most actively pursued disciplines in applied biomedical 
research in general (Bhathena and Spear, 2008; 
Brockmoller and Tzvetkov, 2008; Kroetz et al., 2010; 
Meyer, 2004; Urban, 2010). 
 
 
PHARMCOGENOMICS AND PHARMACOGENETICS 
 
Pharmacogenomics (PGx) is defined as ‘The study of 
variations of DNA and RNA characteristics as related to 
drug response’, and as a subset, pharmacogenetics 
(PGt) is ‘The study of variations in DNA sequence as 
related to drug response’ (Bhathena and Spear, 2008). It 
is widely expected that PGx will facilitate a trend toward 
improved patient outcomes by increasing our under-
standing at the molecular level of both the disease and 
treatment response. As such, PGx is central to persona-
lized medicine strategies (Bhathena and Spear, 2008). 
The term pharmacogenomics was introduced to reflect 
the recent transition from genetics to genomics and the 
use of genome-wide approaches to identify genes that 
contribute to a specific disease or drug response. A 
pharmacogenomics approach may allow a specific drug 
therapy to be targeted to genetically defined subsets of 
patients and may lead to a new disease and treatment 
classification at the molecular level (Eichelbaum et al., 
2006). 
Pharmacogenetics, on the other hand, is essentially the 
discipline which takes the patient’s genetic information of 
drug transporters, drug metabolizing enzymes and drug 
receptors into account to allow for an individualized drug 
therapy leading to optimal choice and dose of the drugs 
in question (Holm, 2008). Observations implying that 
genetic variation was responsible for the diversity in some 
drug responses were already being made five decades 
ago (Meyer, 2004). Therapeutic failure of drugs as well 
as serious adverse side effects of drugs on individuals or 
subpopulations of patients can both have a genetic 
component. The toll that such variation takes in terms of 
individual suffering, high healthcare costs, and even lives, 





GENETIC POLYMORPHISMS AND VARIABILITY IN 
DRUG RESPONSE AND TOXICITY 
 
A great deal of interindividual variability exists in drug 
responses and toxicity. This variation can result from 
genetic, environmental, physiological, and pathophysio-
logical factors (Choi and Song, 2008). In general, genetic 
factors are estimated to account for 15 to 30% of 
interindividual variations in drug disposition and respon-
ses, but for certain drugs, genetic factors can account for 
up to 95% of the interindividual variability in drug disposition 
and effects (Avery et al., 2009; Choi and Song, 2008). 
Accounting for these differences would be highly bene-
ficial, not only for the health care industry, but for patients 
themselves, decreasing the burden of treatment failures 
and adverse events on society (Avery et al., 2009). 
Advances in genotyping technology in the last decade 
have led to the discovery of novel gene variations in drug 
transporters, drug targets, effect or proteins and meta-
bolizing enzymes in the form of single-nucleotide 
polymorphisms (SNPs) that continue to provide insight 
into the biological phenomena that govern drug efficacy 
and toxicity (Avery et al., 2009). 
It has long been recognized that genetic variations in 
drug metabolizing enzymes underlie the inter-individual 
differences in drug response. Certain single nucleotide 
polymorphisms in cytochrome P450 systems, such as 
CYP2D6, are well known to be related to altered drug 
metabolism, unexpected drug effect, and alterations of 
the clinical response and frequency of side effects (Sakata 
et al., 2004). 
Molecular studies in pharmacogenetics have now been 
extended to numerous other human genes including 
those for several drug transport systems (Sakata et al., 
2004). In addition to many drug-metabolizing enzymes, 
drug transport proteins have also consistently replicated 
associations between genetic variants and the clinical 
pharmacokenetics of at least one drug (Bhathena and 
Spear, 2008). It is estimated that there are approximately 
170 genes whose products affect drug disposition, and 
that over half of these are polymorphic (Bhathena and 
Spear, 2008). For example, single nucleotide polynucleo-
tides (SNPs) in the ABC (ATP-binding cassette) 
transporter multidrug resistance-1 (MDR1) genes were 
reported to influence the disposition of digoxin and fexo-
fenadine. Furthermore, SNPs in the SLC (solute carrier) 
transporter OATP-C and OATP-B gene result in the 
decrease of drug transport activity (Sakata et al., 2004). 
 
 
GENETIC POLYMORPHISM OF DRUG 
TRANSPORTERS 
 
Membrane transporters play a critical role in a variety of 
physiological processes. They maintain cellular and 
organismal homeostasis by importing nutrients essential 






products and toxic compounds (Leabman et al., 2003). 
They are also important in drug response as they provide 
the targets for many commonly used drugs and are major 
determinants of drug absorption, distribution, and 
elimination (Leabman et al., 2003). Membrane transport 
proteins share a similar secondary structure, characte-
rized by multiple membrane-spanning domains joined by 
alternating intracellular and extracellular segments 
(‘‘loops’’). Two of the major superfamilies of membrane 
transport proteins are the ABC (ATP-binding cassette) 
transporters, which include MDR1, a protein that pumps 
xenobiotics from cells, and the SLC (solute carrier) trans-
porters, which take up neurotransmitters, nutrients, heavy 
metals, and other substrates into cells (Leabman et al., 
2003). 
Genetic polymorphisms in drug transporter genes have 
increasingly been recognized as a possible mechanism 
accounting for variation in drug response (Shu et al., 
2007). Genetic polymorphism of drug transporters has 
recently attracted interest because these transporters 
play important roles in the gastrointestinal absorption, 
biliary and renal elimination, and distribution to target 
sites of their substrates (Choi and Song, 2008). The aim 
of this research was to clarify the considerable inter-
individual variability in the pharmacokinetics, efficacy, 
and toxicity of drugs (Choi and Song, 2008). There is 
emerging pharmacogenetic evidence now strongly sug-
gesting those membrane transporters are subject to both 
genotypic and phenotypic polymorphism, and that variation 
in drug transporters may be the reason for interindividual 
variability in pharmacokinetic disposition, efficacy, and 




SOLUTE CARRIER TRANSPORTERS 
 
The solute carrier (SLC) superfamily of transporters 
consists of more than 300 members subdivided into 47 
families. They are expressed in most tissues, but 
primarily in the liver, lung, kidney, and intestine. Most 
solute carrier transporters are localized at either the 
basolateral or apical plasma membrane of polarized cells, 
but some are expressed in mitochondria and other 
organelles (Wojtal et al., 2009). Typical SLC transporters 
consist of several trans-membranes α-helices connected 
by intra- and extracellular loops and function as either 
monomers or hetero- or homodimers (Wojtal et al., 2009). 
SLC transporters are membrane-associated transporters 
that facilitate the passage of solutes, including peptides, 
bile acids, amino acids, ions, xenobiotics, drugs, and 
other biologically active compounds, across cell mem-
branes in epithelial tissues, such as intestine and liver 
(Hediger et al., 2004; Koepsell et al., 2007). In the 
intestine, SLCs are critically involved in drug absorption, 
thus determining distribution and pharmacokinetic 
characteristics  of   many   drugs   (Meier   et   al.,  2007).  




Polyspecific organic cation transporters belong to the 
SLC22 family and the MATE family (Koepsell et al., 
2007). Most transporters of the SLC22 family are poly-
specific, transporting multiple different substrates, and 
are subdivided into three groups: organic cation trans-
porters (OCTs), organic anion transporters (OATs), and 
organic zwitterion/cation transporters (OCTNs) (Meier et 
al., 2007). The OCTs include OCT1 (SLC22A1), OCT2 
(SLC22A2) and OCT3 (SLC22A3). The OCTNs include 
OCTN1 (SLC22A4) that may be a proton cation 
exchanger, the Na+-carnitine cotransporter OCTN2 
(SLC22A5) that can also operate as Na+ independent 
transporter for organic cations (Koepsell et al., 2007). 
OCTN1 and OCTN2 have attracted much attention as 
polymorphisms in the genes encoding them have been 
linked to inflammatory bowel disease (Meier et al., 2007). 
The human organic cation transporters, also designated 
as hOCT1, hOCT2, and hOCT3, mediate electrogenic 
transport of small organic cations with different molecular 
structures, independent of sodium gradient. These 
organic cation substrates include clinically important 
therapeutics (e.g., metformin, procainamide, and 
cimetidine), endogenous compounds (e.g., dopamine and 
norepinephrine), as well as toxic substances [e.g., 
tetraethylammonium bromide (TEA)] (Kang et al., 2007). 
The genes encoding the three organic cation transporter 
isoforms (hOCT1, hOCT 2, and hOCT 3) are clustered 
together on the long arm of chromosome 6. Population 
genetics analyses identified numerous single-nucleotide 
polymorphisms (SNPs) in the three genes (Tzvetkov et 
al., 2009). 
Human orthologs of the multidrug and toxin extrusion 
(MATE) family, members of which confer multidrug 
resistance on bacteria, were recently identified and 
named MATE1 (SLC47A1) and MATE2-K (SLC47A2). The 
SLC47A1 and SLC47A2 genes encode for the MATE1 
and MATE2-K proteins, respectively. Both transporters 
are expressed mainly in the renal brush border 
membranes, and are H
+
/organic cation antiporters 
involved in the transport of ionic drugs in the renal 
tubules (Kajiwara et al., 2009). It has been demonstrated 
that the antidiabitic drug metformin is an exceptional 
substrate for MATE1 and MATE2-K and that these pro-
teins play a role in the elimination of metformin into the 
bile (MATE1) and urine [MATE1 and MATE2-K] (Avery et 
al., 2009). Recent studies suggest that interpatient 
variability in response to metformin therapy could be 
related to polymorphisms in the OCT genes and/or the 
MATE genes (Avery et al., 2009).  
The growing number of publications reporting genetic 
population data for the solute carrier transporters shows 
their importance, as well as the increased interest in 
investigating them in most recent pharmaco-
genetics/genomics research projects (Kajiwara et al., 
2009; Kang et al., 2007; Leabman et al., 2003; Meier et 
al., 2007; Sakata et al., 2004; Shu et al., 2007; Toh et al., 
2010;   Wojtal   et   al.,   2009).   These   publications  are  
 




reporting baseline frequency distributions of SNPs of 
genes important in drug transport, discovering new genetic 
variants of these genes, and/or describing genotyping 
projects to identify probable responders or non-responders 




GENETIC ANCESTRY AND BEYOND: PHARMACO-
GENETICS/GENOMICS FROM AFRICA FOR AFRICA 
 
The concepts of race, ethnicity, and ancestry, have long 
had a strong influence on pharmacogenetic discovery 
and on our understanding of population level differences 
in drug response (Urban, 2010). Despite controversy 
surrounding the use of these terms, recognition of inter-
ethnic differences in drug response might be useful in 
establishing public health policies, designing and inter-
preting clinical trials and, possibly, guiding clinicians to 
evaluate prospectively which patients have the greatest 
probability of expressing a variant genotype (Suarez-
Kurtz, 2005). Population based studies can help to 
establish baseline frequency distribution of SNPs of 
genes important in drug metabolism and/or transport. 
Extrapolations of possible clinical implications of the 
baseline frequency distribution of some of the alleles 
based on established phenotypic characteristics could 
guide doctors in drug prescription decision-making and/or 
provide explanations of ethnic-specific adverse effects in 
metropolitan medical practice (Matimba et al., 2008). 
Genomic diversity within sub-Saharan Africa, and for 
that matter the entire African continent, is relatively 
under-studied, despite being home to significant portion 
of human genomic diversity (Hardy et al., 2008). There is 
thus much to be learnt from characterizing human 
genomic variation in this part of Africa, especially with 
regards to health applications (Hardy et al., 2008). South 
Africa in particular contains a wealth of different popula-
tion groups. This fact was recognized in the National 
Biotechnology Strategy Report for South Africa (2002), 
and recommended that the country focus on document-
ting the genomic diversity contained within the local 
indigenous and immigrant populations (Hardy et al., 
2008). The country is indeed home to the indigenous 
Khoisian, Xhosa, Zulu, Venda, and Sotho Pedi groups, 
the Afrikaners and the Cape Coloured, the latter being a 
uniquely admixed population of immigrant Europeans, 
Asians and the indigenous populations (Hardy et al., 
2008). Admixed groups, such as Latinos, African Ameri-
cans, or Cape Coloureds from South Africa, share varying 
proportions of different ancestral populations and their 
genetic complexity can potentially complicate biomedical 
research studies (Via et al., 2009). Their mixed ancestry, 
however, can provide the intrinsic variability needed to 
untangle complex gene-environment interactions, which 
may help to explain the population differences in the 
epidemiology of complex diseases (Via et al., 2009). 





the Department of Biotechnology at the University of the 
Western Cape (South Africa), has been investigating the 
genetic diversity and origins of the Cape local 
communities with a special focus on the Cape Muslim 
population (Abrahams et al., 2010; Benjeddou et al., 
2006; Cloete et al., 2010). The feedback from the investi-
gated communities showed that despite the enthusiasm 
about knowing their genetic ancestry, there is great 
interest in expanding the program to include the investi-
gation of a variety of medical and health implications 
resulting from the genetic diversity of these populations. It 
is widely believed that this type of research will benefit 
the investigated communities as well as the country as a 
whole. The study of the genetic diversity of the solute 
carrier transporter genes and its pharmacogenetic 
implications within the South African and Sub-Saharan 
African populations can be the first step in that direction. 
It will contribute in filling the gap of missing important 
pharmacogenetics data from South Africa and Sub-
Saharan Africa. It is an opportunity to produce original 
research in the area of pharmaco-genetics/genomics in 
Africa for Africa. It is also an excellent opportunity to 
forge balanced and meaningful international collabo-
rations between African researchers and counterparts 
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